Warning letter · FDA Warning Letters, Historical Archive

Bio TE Medical: FDA Warning Letter (May 22, 2017)

Agency action: May 22, 2017Record ID: fda_warning_-d10b923de5b4db98
View official source ↗

What happened

Original notice title

Bio TE Medical 5/22/17

From the archived source record

The inspection revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements regulation, Title 21, Code of Federal Regulations, Part 111 (21 CFR Part 111). These violations cause your dietary supplement products to be adulterated within the meaning of section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C § 342(g)(1)] in that they have been prepared, packed, or held under insanitary conditions that do not meet CGMP regulation for dietary supplements. Furthermore, the labeling for BioTE DIM causes it to be misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] as detailed below. A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). Accordingly, these products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)]. Adulterated Dietary Supplements Even if your BioTE DIM, BiotTE Probiotic, BioTE Iodine Plus and BioTE Omega 3 products did not have therapeutic claims which make them unapproved new drugs, these products and all dietary supplement products that you distribute would still be adulterated under section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing (CGMP) regulations for dietary supplements, Title 21, Code of Federal Regulations, Part 111 (21 CFR Part 111). 1.

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
Historical warning letter; closeout not established by annual index
Source checked
Jul 16, 2026
Record revision
283d527b537d

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
All about DIM; AGE HEALTHIER AND LIVE HAPPIER bioTE Bio-Identical Hormone Balance for Men and Women
Company
Bio TE Medical
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.